FAQ: Nutriband Inc. Presentation at Noble Capital Markets Emerging Growth Virtual Equity Conference
Summary
Nutriband Inc. (NASDAQ: NTRB) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025, featuring a fireside Q&A session and one-on-one investor meetings. This provides investors with direct access to company leadership and insights into Nutriband's development of abuse-deterrent transdermal pharmaceutical products.
What is the main announcement in this content?
Nutriband Inc. (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on October 8, 2025, including a fireside Q&A session and opportunities for registered investors to schedule one-on-one meetings.
When and where is the presentation taking place?
The presentation will occur on Wednesday, October 8, 2025, at 3 p.m. ET as part of the Noble Capital Markets Emerging Growth Virtual Equity Conference, which is a virtual event accessible online.
Who is presenting at the conference?
Serguei Melnik, Chairman of Nutriband Inc., will be presenting and participating in the fireside Q&A session, and he will also be available for one-on-one meetings with registered investors.
How can investors participate in this event?
Interested attendees can register at no cost via the conference’s official site, and registered investors can schedule one-on-one meetings with Chairman Serguei Melnik during the event.
Will the presentation be available for later viewing?
Yes, a video webcast of the presentation will be available on Channelchek, Noble’s investor portal, and archived for 90 days on both Channelchek.com and Nutriband’s website at www.nutriband.com.
What is Nutriband Inc.’s primary business focus?
Nutriband is primarily engaged in developing transdermal pharmaceutical products, with their lead product being an abuse-deterrent fentanyl patch incorporating their AVERSA™ technology to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
What is AVERSA™ technology?
AVERSA™ is Nutriband’s abuse-deterrent technology that can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Where can I find more information about Nutriband and this announcement?
You can view the full press release at https://ibn.fm/MQAEm, visit the company’s website at www.nutriband.com, or access the latest news and updates relating to NTRB in the company’s newsroom at https://ibn.fm/NTRB.
Why is this presentation significant for investors?
This presentation provides investors with direct access to company leadership through the fireside Q&A and one-on-one meetings, offering insights into Nutriband’s development pipeline and business strategy for their abuse-deterrent transdermal pharmaceutical products.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 246609